Fox Run Management L.L.C. Sells 3,224 Shares of Keros Therapeutics, Inc. $KROS

Fox Run Management L.L.C. reduced its position in shares of Keros Therapeutics, Inc. (NASDAQ:KROS) by 14.5% in the 1st quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 18,989 shares of the company’s stock after selling 3,224 shares during the period. Fox Run Management L.L.C.’s holdings in Keros Therapeutics were worth $193,000 at the end of the most recent quarter.

Other large investors have also recently added to or reduced their stakes in the company. Braidwell LP boosted its holdings in shares of Keros Therapeutics by 167.9% in the 4th quarter. Braidwell LP now owns 1,894,439 shares of the company’s stock worth $29,989,000 after acquiring an additional 1,187,199 shares in the last quarter. Federated Hermes Inc. boosted its stake in Keros Therapeutics by 882.3% in the first quarter. Federated Hermes Inc. now owns 1,224,139 shares of the company’s stock worth $12,474,000 after purchasing an additional 1,099,519 shares in the last quarter. Vanguard Group Inc. boosted its stake in Keros Therapeutics by 31.1% in the first quarter. Vanguard Group Inc. now owns 2,566,321 shares of the company’s stock worth $26,151,000 after purchasing an additional 609,212 shares in the last quarter. Lynx1 Capital Management LP bought a new stake in shares of Keros Therapeutics during the fourth quarter worth $8,612,000. Finally, Millennium Management LLC increased its stake in shares of Keros Therapeutics by 53.3% in the fourth quarter. Millennium Management LLC now owns 878,159 shares of the company’s stock valued at $13,901,000 after buying an additional 305,169 shares in the last quarter. 71.56% of the stock is owned by institutional investors.

Keros Therapeutics Price Performance

Shares of NASDAQ KROS opened at $14.23 on Thursday. Keros Therapeutics, Inc. has a fifty-two week low of $9.12 and a fifty-two week high of $72.37. The firm has a market capitalization of $578.02 million, a P/E ratio of 45.90, a P/E/G ratio of 1.78 and a beta of 1.33. The company’s 50 day simple moving average is $13.97 and its 200 day simple moving average is $12.93.

Keros Therapeutics (NASDAQ:KROS) last released its earnings results on Wednesday, August 6th. The company reported ($0.76) EPS for the quarter, topping analysts’ consensus estimates of ($1.14) by $0.38. The firm had revenue of $0.02 million during the quarter, compared to analyst estimates of $3.83 million. Keros Therapeutics had a net margin of 8.06% and a return on equity of 2.96%. The business’s quarterly revenue was up 49002.7% compared to the same quarter last year. During the same quarter in the previous year, the business earned ($1.25) EPS. Sell-side analysts expect that Keros Therapeutics, Inc. will post -4.74 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several research analysts recently issued reports on KROS shares. Bank of America downgraded shares of Keros Therapeutics from a “buy” rating to a “neutral” rating and reduced their price target for the stock from $32.00 to $18.00 in a research report on Tuesday, June 10th. HC Wainwright reduced their target price on shares of Keros Therapeutics from $25.00 to $20.00 and set a “buy” rating on the stock in a research report on Friday, August 8th. Wedbush restated a “neutral” rating and issued a $15.00 price objective on shares of Keros Therapeutics in a research report on Friday, May 30th. Finally, Scotiabank decreased their price objective on Keros Therapeutics from $41.00 to $26.00 and set a “sector outperform” rating on the stock in a research report on Monday, May 12th. Seven investment analysts have rated the stock with a Buy rating and seven have given a Hold rating to the stock. According to MarketBeat.com, Keros Therapeutics currently has a consensus rating of “Moderate Buy” and a consensus price target of $30.00.

Keros Therapeutics Profile

Keros Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis.